Many breast cancer survivors may die of heart disease, doctors warn
(Reuters Health) - The same advances in breast cancer treatment that have dramatically improved survival in recent years have also left a growing number of women vulnerable to potentially fatal cardiovascular problems, the American Heart Association warns.
In women and men, cardiovascular disease is and will remain the leading avoidable cause of premature death in the United States and is rapidly becoming so worldwide. (1) While many women fear breast cancer more than cardiovascular disease, 1 in 8 will develop and 1 in 25 will die from this disease whereas over 1 in 3 will die from coronary heart disease and 1 in 6 from stroke. (2)
Researchers from the German Cancer Research Centre found breast-cancer patients given chemo or radiotherapy have no greater risk of death from heart disease than the average person.
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) Many breast cancer therapies cause damage to the heart. However, in the largest study of its kind so far, scientists from the German Cancer Research Center (DKFZ) in Heidelberg have now shown that the risk of death from heart disease in breast cancer patients following radiotherapy or chemotherapy is no higher than it is among the average population. Good risk management in the hospitals as well as control screenings at short intervals seem to make up for elevated risks.
In conclusion, the present review of Torquati et al (3) shows that even if the number of new publications on shift work and cardiovascular health increases, many of the new studies still include the well- known old sources of bias. Some light is seen in the acknowledgement of the need for better exposure assessment of shift work. The new case–control studies of shift work and breast cancer used interviews to get more precise and relevant information on exposure to night and shift work (7). However, the use of electronic records of working hours would be most optimal. For the cohort studies, we would need to combine t...
Conclusion Although routine implementation of DIBH requires significant resource commitments, it seems to be worthwhile regarding the projected reductions in cardiac mortality.
Conclusions The maximum dose to the LAD was as high as 53Gy, suggesting an increased risk of cardiac morbidity. This study underscores the value of contouring the LAD and the value of the breath hold technique to reduce maximum cardiac doses. Smaller CT cuts (2.5mm) can improve contouring. Larger studies with long-term follow up are needed to determine the radiation tolerance dose for the LAD.
Conclusion: Discordance between guidelines and practice was found regarding prescription of OACs and maintenance of optimal anticoagulation for stroke prevention in our population. Optimal anticoagulation needs to be emphasized on both patients as well as physicians to prevent strokes and achieve better outcomes.Keywords:CHADS2 score,International normalized ratio,Oral Anticoagulants,Valvular heart disease.View:PDF (138.96 KB)Click here to download the PDF file.‹ Breast Cancer and the Heart: Burden on the ChestAssociation between Myocardial Infarction and Dermatoglyphics: A Cross-Sectional Study ›
Journal of Cardiovascular Disease Research,2018,9,1,1-4.DOI:10.5530/jcdr.2018.1.1Published:March 2018Type:Review ArticleBreast Cancer and the Heart: Burden on the ChestAjit Singh,Hashir Kareem,Tom Devasia,Kanav Khera,Sheetal Chauhan,Yeswanth Rao K,andGanesh PAjit Singh*1, Hashir Kareem1, Tom Devasia1, Kanav Khera2, Sheetal Chauhan3, Yeswanth Rao K3, Ganesh P11Department of Cardiology, Kasturba Medical College and Hospital, Manipal Academy of Higher Education, Manipal, Karnataka, INDIA.2Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, INDIA...
No abstract available
Click here for a preview Trastuzumab is a monoclonal antibody targeting the HER2 (human epidermal growth factor receptor 2) used in the treatment of HER2 positive breast cancer. The drug when used in the treatment of early stage breast cancer, reduces recurrences by half and mortality by one third. But trastuzumab trials have shown severe heart failure or cardiac event rate up to 3.9%. Important risk factors for cardiotoxicity with trastuzumab treatment are: Age above 50 years Underlying heart disease or hypertension Baseline left ventricular ejection fraction 50-55% or lower Previous anthracycline therapy Referen...